ArticleJournal for immunotherapy of cancer2026

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Farrukh T Awan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.